From Nasdaq:

The involvement of chipmaker Nvidia in three companies, including Recursion Pharmaceuticals, pushed the smaller company’s stock up nearly 14%, exceeding the S&P 500 index’s 0.6% gain. The stake in Recursion holds an estimated value of $76 million, revealing a substantial investment from Nvidia, which is known for its development of next-generation chips for AI applications.

Nvidia’s investment in Recursion Pharmaceuticals supports the AI industry, as Nvidia is a leading manufacturer of chips for AI applications. While the company’s motivations remain undisclosed, it is likely driven by a desire to help developers succeed. Investors should keep an eye out for potential future investments from Nvidia as it continues to support companies in the AI sector.

The Motley Fool’s Stock Advisor analyst team did not identify Recursion Pharmaceuticals as one of the 10 best stocks for investors to buy now. Stock Advisor provides investors with a blueprint for success and has achieved returns that triple those of the S&P 500 since 2002. As of February 12, 2024, Stock Advisor returns are available for reference.

The author has no position in the mentioned stocks, and The Motley Fool has positions in and recommends Nvidia. The opinions expressed in this article are those of the author and do not reflect those of Nasdaq, Inc.



Read more: Why Recursion Pharmaceuticals Stock Zoomed Higher on Thursday